Tweet
August 13, 2021
Dr. Kathleen Dooling, MD, MPH
Advisory Committee on Immunization Practices
Evidence to Recommendation Framework:
An Additional Dose of mRNA COVID-19 Vaccine Following a Primary Series in Immunocompromised People
FDA: Emergency Use Authorization (EUA) Amendment
Due to insufficient data, the EUA amendment for an additional dose does not apply to Janssen COVID-19 vaccine or to individuals who received Janssen COVID-19 as a primary series. CDC and FDA are actively engaged to ensure that immunocompromised recipients of Janssen COVID-19 vaccine have optimal vaccine protection
Dr. Kathleen Dooling, MD, MPH
Advisory Committee on Immunization Practices
Evidence to Recommendation Framework:
An Additional Dose of mRNA COVID-19 Vaccine Following a Primary Series in Immunocompromised People
FDA: Emergency Use Authorization (EUA) Amendment
- – Other fully vaccinated individuals do not need an additional dose right now
- – Amendment applies to:
– Pfizer-BioNTech COVID-19 vaccine (BNT162b2) (≥12 years old)– Moderna COVID-19 vaccine (mRNA-1273) (≥18 years old)
Due to insufficient data, the EUA amendment for an additional dose does not apply to Janssen COVID-19 vaccine or to individuals who received Janssen COVID-19 as a primary series. CDC and FDA are actively engaged to ensure that immunocompromised recipients of Janssen COVID-19 vaccine have optimal vaccine protection
